Recent Updates
Recently added Catalysts
BIVI Negative Sentiment Score: 25/100

BIOVIE ALERT: Bragar Eagel & Squire, P.C. is Investigating BioVie Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Key Takeaway: Bragar Eagel & Squire, P.C. is investigating BioVie Inc. (NASDAQ: BIVI) on behalf of long-term stockholders due to a class action complaint filed against the company. The complaint alleges that BioVie misled investors about its Phase 3 clinical trial oversight and business operations. Specifically, it accuses the company of not adequately managing the trial, leading to unreliable data and the potential failure to meet primary endpoints. The investigation seeks to determine if the board of directors breached their fiduciary duties during the defined Class Period.

Market Sentiment Analysis

CONCERNS & RISKS

  • Accusations of BioVie failing to conduct proper oversight of its Phase 3 clinical trial.
  • Claims that misleading statements were made regarding the company's business and operations.
  • Alleged significant exclusions from the clinical trial results could lead to failure to meet endpoints.
  • Concerns over the impact of the COVID-19 pandemic on the company's oversight capabilities.

Full Press Release Details

NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against BioVie Inc. (NASDAQ: BIVI) on behalf of long-term stockholders following a class action complaint that was filed against BioVie on January 19, 2024 with a Class Period from August 5, 2021 to November 29, 2023. Our investigation concerns whether the board of directors of BioVie have breached their fiduciary duties to the company.
The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, it is alleged that Defendants misled investors by failing to disclose that (1) BioVie was not conducting proper oversight of its Phase 3 clinical trial; (2) that the COVID-19 pandemic significantly and negatively impacted the Company’s ability to adequately conduct proper oversight of the Phase 3 clinical trial; (3) that due to lack of proper oversight and reliance on contract research organizations, the data from Defendants’ Phase 3 clinical trial faced a greater risk of being unreliable and that the majority of patients would have to be excluded from the clinical trial; (4) that, as a result of the significant exclusions from the trial results, the Phase 3 clinical trial would fail to meet its primary endpoints; and (5) statements about BioVie’s business, operations, prospects, and compliance with current good clinical practices (“cGCP”) were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.
If you are a long-term stockholder of BioVie, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Bragar Eagel & Squire

Frequently Asked Questions

What is the investigation by Bragar Eagel & Squire about?

The investigation concerns potential claims against BioVie Inc. regarding alleged breaches of fiduciary duties by its board of directors.

When was the class action complaint filed against BioVie?

The class action complaint against BioVie was filed on January 19, 2024.

What is the Class Period mentioned in the complaint?

The Class Period spans from August 5, 2021, to November 29, 2023.

What problems does the complaint allege about BioVie's clinical trial?

It claims BioVie did not conduct proper oversight of its Phase 3 clinical trial and faced data reliability issues.

How can BioVie stockholders get more information?

Stockholders can contact Brandon Walker or Marion Passmore via email or phone for more details.

Last updated: Jan 3, 2025